PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors
- Autores
- Perini, Valentina; Schacke, Michelle; Liddle, Pablo; Vilchez Larrea, Salomé Catalina; Keszenman, Deborah J.; Lafon Hughes, Laura
- Año de publicación
- 2020
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Poly(ADP-ribosyl)polymerase (PARP) synthesizes poly(ADP-ribose) (PAR), which is anchored to proteins. PAR facilitates multiprotein complexes’ assembly. Nuclear PAR affects chromatin’s structure and functions, including transcriptional regulation. In response to stress, particularly genotoxic stress, PARP activation facilitates DNA damage repair. The PARP inhibitor Olaparib (OLA) displays synthetic lethality with mutated homologous recombination proteins (BRCA-1/2), base excision repair proteins (XRCC1, Polβ), and canonical nonhomologous end joining (LigIV). However, the limits of synthetic lethality are not clear. On one hand, it is unknown whether any limiting factor of homologous recombination can be a synthetic PARP lethality partner. On the other hand, some BRCA-mutated patients are not responsive to OLA for still unknown reasons. In an effort to help delineate the boundaries of synthetic lethality, we have induced DNA damage in VERO cells with the radiomimetic chemotherapeutic agent bleomycin (BLEO). A VERO subpopulation was resistant to BLEO, BLEO + OLA, and BLEO + OLA + ATM inhibitor KU55933 + DNA-PK inhibitor KU-0060648 + LigIV inhibitor SCR7 pyrazine. Regarding the mechanism(s) behind the resistance and lack of synthetic lethality, some hypotheses have been discarded and alternative hypotheses are suggested.
Fil: Perini, Valentina. Instituto de Investigaciones Biológicas "Clemente Estable"; Uruguay
Fil: Schacke, Michelle. Instituto de Investigaciones Biológicas "Clemente Estable"; Uruguay
Fil: Liddle, Pablo. Instituto de Investigaciones Biológicas "Clemente Estable"; Uruguay
Fil: Vilchez Larrea, Salomé Catalina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; Argentina
Fil: Keszenman, Deborah J.. Universidad de la Republica. Centro Universitario del Litoral Norte.; Uruguay
Fil: Lafon Hughes, Laura. Instituto de Investigaciones Biológicas "Clemente Estable"; Uruguay - Materia
-
CDKN2A
KU-0060648
KU55933
OLAPARIB
PARP-1
SCR7 PYRAZINE
VERO CELLS
POLY(ADP-RIBOSYLATION)
RESISTANCE
SYNERGISM - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/127964
Ver los metadatos del registro completo
id |
CONICETDig_10b2a36e0576e74c9a467c7aaa2e551c |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/127964 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV InhibitorsPerini, ValentinaSchacke, MichelleLiddle, PabloVilchez Larrea, Salomé CatalinaKeszenman, Deborah J.Lafon Hughes, LauraCDKN2AKU-0060648KU55933OLAPARIBPARP-1SCR7 PYRAZINEVERO CELLSPOLY(ADP-RIBOSYLATION)RESISTANCESYNERGISMhttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Poly(ADP-ribosyl)polymerase (PARP) synthesizes poly(ADP-ribose) (PAR), which is anchored to proteins. PAR facilitates multiprotein complexes’ assembly. Nuclear PAR affects chromatin’s structure and functions, including transcriptional regulation. In response to stress, particularly genotoxic stress, PARP activation facilitates DNA damage repair. The PARP inhibitor Olaparib (OLA) displays synthetic lethality with mutated homologous recombination proteins (BRCA-1/2), base excision repair proteins (XRCC1, Polβ), and canonical nonhomologous end joining (LigIV). However, the limits of synthetic lethality are not clear. On one hand, it is unknown whether any limiting factor of homologous recombination can be a synthetic PARP lethality partner. On the other hand, some BRCA-mutated patients are not responsive to OLA for still unknown reasons. In an effort to help delineate the boundaries of synthetic lethality, we have induced DNA damage in VERO cells with the radiomimetic chemotherapeutic agent bleomycin (BLEO). A VERO subpopulation was resistant to BLEO, BLEO + OLA, and BLEO + OLA + ATM inhibitor KU55933 + DNA-PK inhibitor KU-0060648 + LigIV inhibitor SCR7 pyrazine. Regarding the mechanism(s) behind the resistance and lack of synthetic lethality, some hypotheses have been discarded and alternative hypotheses are suggested.Fil: Perini, Valentina. Instituto de Investigaciones Biológicas "Clemente Estable"; UruguayFil: Schacke, Michelle. Instituto de Investigaciones Biológicas "Clemente Estable"; UruguayFil: Liddle, Pablo. Instituto de Investigaciones Biológicas "Clemente Estable"; UruguayFil: Vilchez Larrea, Salomé Catalina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; ArgentinaFil: Keszenman, Deborah J.. Universidad de la Republica. Centro Universitario del Litoral Norte.; UruguayFil: Lafon Hughes, Laura. Instituto de Investigaciones Biológicas "Clemente Estable"; UruguayMDPI AG2020-11-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/127964Perini, Valentina; Schacke, Michelle; Liddle, Pablo; Vilchez Larrea, Salomé Catalina; Keszenman, Deborah J.; et al.; PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors; MDPI AG; International Journal of Molecular Sciences; 21; 21; 5-11-2020; 1-221422-0067CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/1422-0067/21/21/8288info:eu-repo/semantics/altIdentifier/doi/10.3390/ijms21218288info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:01:13Zoai:ri.conicet.gov.ar:11336/127964instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:01:13.521CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors |
title |
PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors |
spellingShingle |
PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors Perini, Valentina CDKN2A KU-0060648 KU55933 OLAPARIB PARP-1 SCR7 PYRAZINE VERO CELLS POLY(ADP-RIBOSYLATION) RESISTANCE SYNERGISM |
title_short |
PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors |
title_full |
PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors |
title_fullStr |
PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors |
title_full_unstemmed |
PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors |
title_sort |
PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors |
dc.creator.none.fl_str_mv |
Perini, Valentina Schacke, Michelle Liddle, Pablo Vilchez Larrea, Salomé Catalina Keszenman, Deborah J. Lafon Hughes, Laura |
author |
Perini, Valentina |
author_facet |
Perini, Valentina Schacke, Michelle Liddle, Pablo Vilchez Larrea, Salomé Catalina Keszenman, Deborah J. Lafon Hughes, Laura |
author_role |
author |
author2 |
Schacke, Michelle Liddle, Pablo Vilchez Larrea, Salomé Catalina Keszenman, Deborah J. Lafon Hughes, Laura |
author2_role |
author author author author author |
dc.subject.none.fl_str_mv |
CDKN2A KU-0060648 KU55933 OLAPARIB PARP-1 SCR7 PYRAZINE VERO CELLS POLY(ADP-RIBOSYLATION) RESISTANCE SYNERGISM |
topic |
CDKN2A KU-0060648 KU55933 OLAPARIB PARP-1 SCR7 PYRAZINE VERO CELLS POLY(ADP-RIBOSYLATION) RESISTANCE SYNERGISM |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/1.6 https://purl.org/becyt/ford/1 |
dc.description.none.fl_txt_mv |
Poly(ADP-ribosyl)polymerase (PARP) synthesizes poly(ADP-ribose) (PAR), which is anchored to proteins. PAR facilitates multiprotein complexes’ assembly. Nuclear PAR affects chromatin’s structure and functions, including transcriptional regulation. In response to stress, particularly genotoxic stress, PARP activation facilitates DNA damage repair. The PARP inhibitor Olaparib (OLA) displays synthetic lethality with mutated homologous recombination proteins (BRCA-1/2), base excision repair proteins (XRCC1, Polβ), and canonical nonhomologous end joining (LigIV). However, the limits of synthetic lethality are not clear. On one hand, it is unknown whether any limiting factor of homologous recombination can be a synthetic PARP lethality partner. On the other hand, some BRCA-mutated patients are not responsive to OLA for still unknown reasons. In an effort to help delineate the boundaries of synthetic lethality, we have induced DNA damage in VERO cells with the radiomimetic chemotherapeutic agent bleomycin (BLEO). A VERO subpopulation was resistant to BLEO, BLEO + OLA, and BLEO + OLA + ATM inhibitor KU55933 + DNA-PK inhibitor KU-0060648 + LigIV inhibitor SCR7 pyrazine. Regarding the mechanism(s) behind the resistance and lack of synthetic lethality, some hypotheses have been discarded and alternative hypotheses are suggested. Fil: Perini, Valentina. Instituto de Investigaciones Biológicas "Clemente Estable"; Uruguay Fil: Schacke, Michelle. Instituto de Investigaciones Biológicas "Clemente Estable"; Uruguay Fil: Liddle, Pablo. Instituto de Investigaciones Biológicas "Clemente Estable"; Uruguay Fil: Vilchez Larrea, Salomé Catalina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; Argentina Fil: Keszenman, Deborah J.. Universidad de la Republica. Centro Universitario del Litoral Norte.; Uruguay Fil: Lafon Hughes, Laura. Instituto de Investigaciones Biológicas "Clemente Estable"; Uruguay |
description |
Poly(ADP-ribosyl)polymerase (PARP) synthesizes poly(ADP-ribose) (PAR), which is anchored to proteins. PAR facilitates multiprotein complexes’ assembly. Nuclear PAR affects chromatin’s structure and functions, including transcriptional regulation. In response to stress, particularly genotoxic stress, PARP activation facilitates DNA damage repair. The PARP inhibitor Olaparib (OLA) displays synthetic lethality with mutated homologous recombination proteins (BRCA-1/2), base excision repair proteins (XRCC1, Polβ), and canonical nonhomologous end joining (LigIV). However, the limits of synthetic lethality are not clear. On one hand, it is unknown whether any limiting factor of homologous recombination can be a synthetic PARP lethality partner. On the other hand, some BRCA-mutated patients are not responsive to OLA for still unknown reasons. In an effort to help delineate the boundaries of synthetic lethality, we have induced DNA damage in VERO cells with the radiomimetic chemotherapeutic agent bleomycin (BLEO). A VERO subpopulation was resistant to BLEO, BLEO + OLA, and BLEO + OLA + ATM inhibitor KU55933 + DNA-PK inhibitor KU-0060648 + LigIV inhibitor SCR7 pyrazine. Regarding the mechanism(s) behind the resistance and lack of synthetic lethality, some hypotheses have been discarded and alternative hypotheses are suggested. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-11-05 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/127964 Perini, Valentina; Schacke, Michelle; Liddle, Pablo; Vilchez Larrea, Salomé Catalina; Keszenman, Deborah J.; et al.; PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors; MDPI AG; International Journal of Molecular Sciences; 21; 21; 5-11-2020; 1-22 1422-0067 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/127964 |
identifier_str_mv |
Perini, Valentina; Schacke, Michelle; Liddle, Pablo; Vilchez Larrea, Salomé Catalina; Keszenman, Deborah J.; et al.; PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors; MDPI AG; International Journal of Molecular Sciences; 21; 21; 5-11-2020; 1-22 1422-0067 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/1422-0067/21/21/8288 info:eu-repo/semantics/altIdentifier/doi/10.3390/ijms21218288 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
MDPI AG |
publisher.none.fl_str_mv |
MDPI AG |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844613803651629056 |
score |
13.070432 |